# Escugen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/escugen

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Total disclosed funding: $14M
- Latest round: Series A (May 31, 2023)
- Investors on record: 3

## About

Established in 2017 based in Shanghai, China, is a biopharmaceutical company that develops antibody drugs for malignancies and other areas. The company develops drugs mainly by target innovation and specific combination therapy to expand differentiated clinical pathways, and has an entrepreneurial team covering the entire professional chain of biologics R&D. In May 2023, it raised CNY 100 million in series A+ funding led by Toposcend Capital.

The company is mainly developing new drugs for innovative ADCs and currently has three pipeline products in clinical trials. The pioneer pipeline ESG401 is an ADC targeting TROP-2, which has efficacy in triple negative breast cancer and HR positive breast cancer. Another clinical-stage pipeline, ESG206, targets relapse-resistant and refractory lymphomas and leukemias and can be further expanded to multiple autoimmune diseases. ESG103 single-domain antibody will be combined with our partner's proprietary new drug to treat major oncology indications not covered by similar drugs.

## Funding rounds

- Series A, May 31, 2023, $14M — Lotus Lake Capital, Toposcend Capital, Shanghai Zhangjiang Technology Venture Investment Co.,Ltd.

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- Toposcend Capital (https://capitalatlas.ai/funds/toposcend-capital) — Series A
- Shanghai Zhangjiang Technology Venture Investment Co.,Ltd. — Series A